Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Accounts Payables (2016 - 2025)

Traws Pharma (TRAW) has disclosed Accounts Payables for 14 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • For Q4 2025, Accounts Payables fell 30.94% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $5.7 million, down 30.94%, while the annual FY2025 figure was $5.7 million, 30.94% down from the prior year.
  • Accounts Payables hit $5.7 million in Q4 2025 for Traws Pharma, up from $5.1 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $8.2 million in Q4 2024 and bottomed at $2.8 million in Q4 2021.
  • Average Accounts Payables over 5 years is $5.0 million, with a median of $5.0 million recorded in 2023.
  • Year-over-year, Accounts Payables tumbled 42.95% in 2021 and then soared 68.86% in 2023.
  • Traws Pharma's Accounts Payables stood at $2.8 million in 2021, then surged by 40.01% to $3.9 million in 2022, then skyrocketed by 45.57% to $5.6 million in 2023, then soared by 45.68% to $8.2 million in 2024, then tumbled by 30.94% to $5.7 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $5.7 million, $5.1 million, and $4.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.